41 Serious Infections and Associated Risk Factors in Patients Receiving Infliximab and Immunotherapies for Children With Inflammatory Bowel Disease: Develop Registry Data
Robert N. Baldassano(Children's Hospital of Philadelphia), Harland S. Winter(Massachusetts General Hospital), Jeffrey S. Hyams(Connecticut Children's Medical Center), William A. Faubion(Mayo Clinic in Arizona), Johanna C. Escher(Erasmus MC - Sophia Children’s Hospital), James Markowitz, Frank Ruemmele(Hôpital Necker-Enfants Malades), Gigi Veereman, Anja Geldhof, Salvatore Cucchiara(Massachusetts General Hospital), Sibylle Koletzko(LMU Klinikum), Anne M. Griffiths(University of Toronto), Marla Dubinsky(Cedars-Sinai Medical Center), Richard B. Colletti(Greenville College), P. Callegari, Benjamin D. Gold(Emory University), Mark R. Molenda, Kezhen L. Tang(Janssen (United States)), Subra Kugathasan(Children's Healthcare of Atlanta), John Fell(Chelsea and Westminster Hospital), Richard Wright(Center for Applied Linguistics)
Cited by 8
Related Papers
Human gut microbiome viewed across age and geography
|Nature|2012|7.9k
Linking Long-Term Dietary Patterns with Gut Microbial Enterotypes
|Science|2011|6.6k
The Treatment-Naive Microbiome in New-Onset Crohn’s Disease
|Cell Host & Microbe|2014|3.3k